Intraventricular Delivery and CRISPR-Cas9 Disruption of PD-1 is Required for CAR T-cell Efficacy in Glioblastoma

被引：0
|
作者：
Choi, Bryan D.
Yu, Xiaoling
Nahed, Brian V.
Cahill, Daniel P.
Curry, William T.
Carter, Bob S.
Maus, Marcela V.
机构：
来源：
NEUROSURGERY | 2020年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
823
引用
收藏
页码：286 / 286
页数：1
相关论文
共 50 条
  • [1] Intraventricular Delivery and CRISPR-Cas9 Disruption of PD-1 is required for CAR T-cell Efficacy in Glioblastoma
    Choi, Bryan
    Yu, Xiaoling
    Castano, Anna
    Bouffard, Amanda
    Frigault, Matthew
    Schmidts, Andrea
    Curry, William
    Carter, Bob
    Maus, Marcela
    JOURNAL OF NEUROSURGERY, 2020, 132 (04) : 7 - 7
  • [2] CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
    Choi, Bryan D.
    Yu, Xiaoling
    Castano, Ana P.
    Darr, Henia
    Henderson, Daniel B.
    Bouffard, Amanda A.
    Larson, Rebecca C.
    Scarfo, Irene
    Bailey, Stefanie R.
    Gerhard, Genevieve M.
    Frigault, Matthew J.
    Leick, Mark B.
    Schmidts, Andrea
    Sagert, Jason G.
    Curry, William T.
    Carter, Bob S.
    Maus, Marcela, V
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [3] CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
    Shu Su
    Bian Hu
    Jie Shao
    Bin Shen
    Juan Du
    Yinan Du
    Jiankui Zhou
    Lixia Yu
    Lianru Zhang
    Fangjun Chen
    Huizi Sha
    Lei Cheng
    Fanyan Meng
    Zhengyun Zou
    Xingxu Huang
    Baorui Liu
    Scientific Reports, 6
  • [4] CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
    Su, Shu
    Hu, Bian
    Shao, Jie
    Shen, Bin
    Du, Juan
    Du, Yinan
    Zhou, Jiankui
    Yu, Lixia
    Zhang, Lianru
    Chen, Fangjun
    Sha, Huizi
    Cheng, Lei
    Meng, Fanyan
    Zou, Zhengyun
    Huang, Xingxu
    Liu, Baorui
    SCIENTIFIC REPORTS, 2016, 6
  • [5] CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
    Hu, Wanghong
    Zi, Zhenguo
    Jin, Yanling
    Li, Gaoxin
    Shao, Kang
    Cai, Qiliang
    Ma, Xiaojing
    Wei, Fang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) : 365 - 377
  • [6] CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
    Wanghong Hu
    Zhenguo Zi
    Yanling Jin
    Gaoxin Li
    Kang Shao
    Qiliang Cai
    Xiaojing Ma
    Fang Wei
    Cancer Immunology, Immunotherapy, 2019, 68 : 365 - 377
  • [7] Correction: Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
    Shu Su
    Bian Hu
    Jie Shao
    Bin Shen
    Juan Du
    Yinan Du
    Jiankui Zhou
    Lixia Yu
    Lianru Zhang
    Fangjun Chen
    Huizi Sha
    Lei Cheng
    Fanyan Meng
    Zhengyun Zou
    Xingxu Huang
    Baorui Liu
    Scientific Reports, 7
  • [8] CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
    Zhang, Yongping
    Zhang, Xingying
    Cheng, Chen
    Mu, Wei
    Liu, Xiaojuan
    Li, Na
    Wei, Xiaofei
    Liu, Xiang
    Xia, Changqing
    Wang, Haoyi
    FRONTIERS OF MEDICINE, 2017, 11 (04) : 554 - 562
  • [9] CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
    Yongping Zhang
    Xingying Zhang
    Chen Cheng
    Wei Mu
    Xiaojuan Liu
    Na Li
    Xiaofei Wei
    Xiang Liu
    Changqing Xia
    Haoyi Wang
    Frontiers of Medicine, 2017, 11 : 554 - 562
  • [10] CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients (vol 6, 20070, 2017)
    Su, Shu
    Hu, Bian
    Shao, Jie
    Shen, Bin
    Du, Juan
    Du, Yinan
    Zhou, Jiankui
    Yu, Lixia
    Zhang, Lianru
    Chen, Fangjun
    Sha, Huizi
    Cheng, Lei
    Meng, Fanyan
    Zou, Zhengyun
    Huang, Xingxu
    Liu, Baorui
    SCIENTIFIC REPORTS, 2017, 7
12345